Safety and efficacy of persistent atrial fibrillation ablation using the second-generation cryoballoon
- 110 Downloads
The second-generation cryoballoon (CB) is increasingly used for treatment of persistent atrial fibrillation (AF). Data regarding the clinical outcome and mechanism of arrhythmia recurrence following persistent AF ablation using CB is sparse. In this study, we aimed to assess the efficacy of CB and mechanisms of atrial tachyarrhythmia (ATA) recurrence in patients with persistent AF.
Methods and results
A total of 133 patients (66 ± 10 years, 60% male) with symptomatic persistent AF, who were scheduled for PVI using the second-generation CB were enrolled. Follow-up included 24 h Holter recording at 3, 6 and 12 months. Any documented episode of ATA lasting more than 30 s was considered as a recurrent arrhythmic event. All targeted veins were isolated (100%). Phrenic nerve palsy with recovery during follow-up occurred in six patients (4.5%), no patient experienced tamponade or a cerebrovascular event. During 12.6 ± 5.4 months of follow-up, 89/133 (67%) patients were free of ATA recurrences. Multivariable analysis revealed recurrence in the blanking period (HR 11.46, 0.95 CI 3.92–33.49, p < 0.001), presence of cardiomyopathy (HR 2.75, 0.95 CI 1.09–6.96, p = 0.032) and PV abnormality (HR 3.56, 0.95 CI 1.21–10.43, p = 0.021) as predictors for late recurrence.
In patients with persistent AF, second-generation cryoballoon use is associated with an excellent safety profile and favorable outcomes. Arrhythmia recurrence during the blanking period, presence of cardiomyopathy and PV abnormality were independent predictors of long-term AF recurrence.
KeywordsPersistent atrial fibrillation Cryoballoon ablation
European Heart Rhythm Association
Implantable cardioverter defibrillator
International normalized ratio
Left common pulmonary vein
Left inferior pulmonary vein
Left superior pulmonary vein
Left ventricular ejection fraction
Phrenic nerve palsy
Pulmonary vein isolation
Right inferior pulmonary vein
Right middle pulmonary vein
Right superior pulmonary vein
K. Yalin recieved research and educational grant from Turkish Society of Cardiology. E. Lyan received travel grants and Speaker’s Bureau Honoraria from Biosense Webster, Medtronic, Boston Scientific. R. Tilz received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, Sentrheart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sanofi Aventis.
- 1.Paulus Kirchhof, Authors/Task Force Members; Stefano Benussi, Authors/Task Force Members; Dipak Kotecha, Authors/Task Force Members; Anders Ahlsson, Authors/Task Force Members; Dan Atar, Authors/Task Force Members; Barbara Casadei, Authors/Task Force Members; Manuel Castella, Authors/Task Force Members; Hans-Christoph Diener, Authors/Task Force Members; Hein Heidbuchel, Authors/Task Force Members; Jeroen Hendriks, Authors/Task Force Members; Gerhard Hindricks, Authors/Task Force Members; Antonis S. Manolis, Authors/Task Force Members; Jonas Oldgren, Authors/Task Force Members; Bogdan Alexandru Popescu, Authors/Task Force Members; Ulrich Schotten, Authors/Task Force Members; Bart Van Putte, Authors/Task Force Members; Panagiotis Vardas, Authors/Task Force Members; Stefan Agewall, Document Reviewers; John Camm, Document Reviewers; Gonzalo Baron Esquivias, Document Reviewers; Werner Budts, Document Reviewers; Scipione Carerj, Document Reviewers; Filip Casselman, Document Reviewers; Antonio Coca, Document Reviewers; Raffaele De Caterina, Document Reviewers; Spiridon Deftereos, Document Reviewers; Dobromir Dobrev, Document Reviewers; José M. Ferro, Document Reviewers; Gerasimos Filippatos, Document Reviewers; Donna Fitzsimons, Document Reviewers; Bulent Gorenek, Document Reviewers; Maxine Guenoun, Document Reviewers; Stefan H. Hohnloser, Document Reviewers; Philippe Kolh, Document Reviewers; Gregory Y. H. Lip, Document Reviewers; Athanasios Manolis, Document Reviewers; John McMurray, Document Reviewers; Piotr Ponikowski, Document Reviewers; Raphael Rosenhek, Document Reviewers; Frank Ruschitzka, Document Reviewers; Irina Savelieva, Document Reviewers; Sanjay Sharma, Document Reviewers; Piotr Suwalski, Document Reviewers; Juan Luis Tamargo, Document Reviewers; Clare J. Taylor, Document Reviewers; Isabelle C. Van Gelder, Document Reviewers; Adriaan A. Voors, Document Reviewers; Stephan Windecker, Document Reviewers; Jose Luis Zamorano, Document Reviewers; Katja Zeppenfeld, Document Reviewers; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962Google Scholar
- 8.Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P (2015) STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372:1812–1822CrossRefPubMedGoogle Scholar
- 11.Ciconte G, Baltogiannis G, de Asmundis C, Sieira J, Conte G, Di Giovanni G et al (2015) Circumferential pulmonary vein isolation as index procedure for persistent atrial fibrillation: a comparison between radiofrequency catheter ablation and second-generation cryoballoon ablation. Europace 17:559–565CrossRefPubMedGoogle Scholar
- 15.Aytemir K, Oto A, Canpolat U, Sunman H, Yorgun H, Şahiner L, Kaya EB (2013) Immediate and medium-term outcomes of cryoballoon-based pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation: single-centre experience. J Interv Card Electrophysiol 38:187–195CrossRefPubMedGoogle Scholar
- 16.Metzner A, Heeger CH, Wohlmuth P, Reißmann B, Rillig A, Tilz RR, Mathew S, Lemes C, Deiß S, Maurer T, Saguner A, Ouyang F, Kuck KH, Wißner E (2016) Two-year outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon: lessons from the bonus freeze protocol. Clin Res Cardiol 105(1):72–78CrossRefPubMedGoogle Scholar
- 19.Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG; STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713–1723CrossRefPubMedGoogle Scholar
- 21.Heeger CH, Tscholl V, Wissner E, Fink T, Rottner L, Wohlmuth P et al (2017) Acute efficacy, safety, and long-term clinical outcomes using the second-generation cryoballoon for pulmonary vein isolation in patients with a left common pulmonary vein: a multicenter study. Heart Rhythm 14:1111–1118CrossRefPubMedGoogle Scholar
- 23.Guler TE, Aksu T, Yalin K, Golcuk SE, Mutluer FO, Bozyel S (2017) Combined cryoballoon and radiofrequency ablation versus alone radiofrequency ablation for long-standing atrial fibrillation. Am J Med Sci (epub of print)Google Scholar
- 24.Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM (2012) Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation) trial. J Am Coll Cardiol 60:628–636CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Guhl EN, Siddoway D, Adelstein E, Bazaz R, Mendenhall GS, Nemec J, Saba S, Schwartzman D, Voigt A, Wang NC, Jain SK (2016) Incidence and predictors of complications during cryoballoon pulmonary vein isolation for atrial fibrillation. J Am Heart Assoc 5(7). https://doi.org/10.1161/JAHA.116.003724